Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CLPP | Q16740 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982399 | 0.90 | C5AR1 (0.61) | C5AR1MEN1KMT2ACLPPACHE | |
| SCHEMBL1911807 | 0.83 | KMT2A (0.52) | C5AR1MEN1KMT2ACLPPACHE | |
| SCHEMBL30767848 | 0.81 | KMT2A (0.53) | C5AR1MEN1KMT2ACLPPACHE | |
| SCHEMBL322777 | 0.81 | KMT2A (0.53) | C5AR1MEN1KMT2ACLPPACHE | |
| SCHEMBL15721594 | 0.81 | C5AR1 (0.49) | C5AR1MEN1KMT2ACLPPACHE | |
| SCHEMBL14660387 | 0.81 | C5AR1 (1.00) | C5AR1MEN1KMT2ACLPPNPC1 | |
| SCHEMBL1911808 | 0.80 | KMT2A (0.52) | C5AR1MEN1KMT2ACLPPACHE | |
| SCHEMBL2868214 | 0.80 | KMT2A (0.59) | C5AR1MEN1KMT2ACLPPACHE | |
| SCHEMBL14872729 | 0.80 | KMT2A (0.52) | C5AR1MEN1KMT2ACLPPACHE | |
| SCHEMBL323116 | 0.78 | C5AR1 (0.46) | C5AR1MEN1KMT2ACLPPACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136639-B1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2016-03-09 | — | — | EP | disclosed |
| EP-2136639-B1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-8653091-B2 | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653091-B2 | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8653091-B2 | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2014-02-18 | — | — | US | disclosed |
| EP-2139334-B1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2139334-B1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | WEI ZHI-LIANG (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | WEI ZHI-LIANG (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | WEI ZHI-LIANG (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-2139334-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2136639-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008130481-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130481-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008123963-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008123963-A1 | PYRID-2-YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009432-A1 | PYRID-2YL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | IL1B, C5, HTR2C | C5AR1 242/4885MEN1 2319/4885KMT2A 2758/4885 |
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | IL1B, IL1A, CRHR1 | C5AR1 55/4885MEN1 1650/4885KMT2A 3089/4885 |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | CNR2, CNR1, CBR1 | C5AR1 132/4885MEN1 2822/4885KMT2A 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.